| For: | Kamenz T, Caca K, Blüthner T, Tannapfel A, Mössner J, Wiedmann M. Expression of c-kit receptor in human cholangiocarcinoma and in vivo treatment with imatinib mesilate in chimeric mice. World J Gastroenterol 2006; 12(10): 1583-1590 [PMID: 16570351 DOI: 10.3748/wjg.v12.i10.1583] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v12/i10/1583.htm |
| Number | Citing Articles |
| 1 |
Christian D. Fingas, Joachim C. Mertens, Nataliya Razumilava, Steven F. Bronk, Alphonse E. Sirica, Gregory J. Gores. TargetingPDGFR‐β in Cholangiocarcinoma. Liver International 2012; 32(3) doi: 10.1111/j.1478-3231.2011.02687.x
|
| 2 |
Wen-Ling Kuo, Ming-Chin Yu, Ju-Fang Lee, Chi-Neu Tsai, Tse-Ching Chen, Miin-Fu Chen. Imatinib Mesylate Improves Liver Regeneration and Attenuates Liver Fibrogenesis in CCL4-Treated Mice. Journal of Gastrointestinal Surgery 2012; 16(2) doi: 10.1007/s11605-011-1764-7
|
| 3 |
Marcus Wiedmann, Jürgen Feisthammel, Thilo Blüthner, Andrea Tannapfel, Thomas Kamenz, Annett Kluge, Joachim Mössner, Karel Caca. Novel targeted approaches to treating biliary tract cancer: the dual epidermal growth factor receptor and ErbB-2 tyrosine kinase inhibitor NVP-AEE788 is more efficient than the epidermal growth factor receptor inhibitors gefitinib and erlotinib. Anti-Cancer Drugs 2006; 17(7) doi: 10.1097/01.cad.0000217433.48870.37
|
| 4 |
Luca Fabris, Massimiliano Cadamuro, Lidia Moserle, James Dziura, Xiangyu Cong, Luisa Sambado, Giorgia Nardo, Aurelio Sonzogni, Michele Colledan, Alberto Furlanetto, Nicolò Bassi, Marco Massani, Umberto Cillo, Claudia Mescoli, Stefano Indraccolo, Massimo Rugge, Lajos Okolicsanyi, Mario Strazzabosco. Nuclear expression of S100A4 calcium-binding protein increases cholangiocarcinoma invasiveness and metastasization. Hepatology 2011; 54(3) doi: 10.1002/hep.24466
|
| 5 |
Jan-Hendrik Egberts, Bodo Schniewind, Clemens Schafmayer, Marie-Luise Kruse, Bence Sipos, Fred Fändrich, Holger Kalthoff, Jürgen Tepel. Establishment of a novel orthotopic xenograft model of human gallbladder carcinoma. Clinical & Experimental Metastasis 2007; 24(3) doi: 10.1007/s10585-007-9058-x
|
| 6 |
Jürgen Feisthammel, Konrad Schoppmeyer, Joachim Mössner, Manfred Schulze, Karel Caca, Marcus Wiedmann. Irinotecan With 5-FU/FA in Advanced Biliary Tract Adenocarcinomas. American Journal of Clinical Oncology 2007; 30(3) doi: 10.1097/01.coc.0000258124.72884.7a
|
| 7 |
Marcus Wiedmann, Helmut Witzigmann, Joachim Mössner. Clinical Hepatology. 2010; doi: 10.1007/978-3-642-04519-6_62
|
| 8 |
Florian Eckel, Roland M Schmid. Emerging drugs for biliary cancer. Expert Opinion on Emerging Drugs 2007; 12(4) doi: 10.1517/14728214.12.4.571
|
| 9 |
Federico Moriconi, Pierluigi Ramadori, Frank C. Schultze, Martina Blaschke, Ahmad Amanzada, Sajjad Khan, Giuliano Ramadori. Characterization of the erythropoietin/erythropoietin receptor axis in a rat model of liver damage and cholangiocarcinoma development. Histochemistry and Cell Biology 2013; 139(3) doi: 10.1007/s00418-012-1037-x
|
| 10 |
Faezeh Hosseinzadeh, Jafar Ai, Abbas Hajifathali, Samad Muhammadnejad, Somayeh Ebrahimi-Barough, Iman Seyhoun, Tahereh Komeili Movahed, Sadegh Shirian, Fatemeh Hosseinzadeh, Sajjad Ahmadpour, Mohammadreza Alijani, Javad Verdi. The effects of Sorafenib and Natural killer cell co-injection in combinational treatment of hepatocellular carcinoma; an in vivo approach. Pharmacological Reports 2022; 74(2) doi: 10.1007/s43440-021-00335-y
|